November 10-15

The official news source of

ACR Convergence 2023

San Diego, CA

  • Novel URAT1 Inhibitor Successful in Proof-of-Concept Trial & More Late-Breaking Abstracts

    Novel URAT1 Inhibitor Successful in Proof-of-Concept Trial & More Late-Breaking Abstracts

    Robert Keenan, MD, MPH, MBA, presented one of five late-breaking abstracts on the final day of ACR Convergence 2023. He discussed research showing the efficacy of AR882 in gout compared to allopurinol. Other cutting-edge science in the session related to immunosuppressant use in long-term IgG4-RD, TLR7/8 inhibition in cutaneous lupus erythematosus, long-acting steroid injections for…

    Read More

More news from #ACR23


Poster Spotlight